Transitioning From Cyclosporine to Alefacept in Psoriasis

Phase 2

Completed

• Conditions: Psoriasis

• Registration Number: NCT00143806
• Lead Sponsor: University of Medicine and Dentistry of New Jersey

Brief Summary

The purpose of this study is to devise a safe and effective method for transitioning patients from cyclosporine to alefacept.

Detailed Description

The purpose of this study is to devise a safe and effective method for transitioning patients from cyclosporine to alefacept. Patients in the study are well controlled on cyclosporine and desire to switch to alefacept. The study is done in three phases. In Phase 1 (12 week duration) the two drugs will be overlapped, with cyclosporine slowly tapering. Both drugs will be discontinued after 12 weeks. In Phase 2 (12 weeks duration), patients are off both drugs. In Phase 3 (24 weeks long), patients are on a second course of alefacept alone for 12 weeks and then off for 12 weeks. Topical and UV light treatments are allowed throughout the study. Total length of study is one year.

Study Timeline

• Study Start: 2003-10
• Study First Submitted: 2005-08-31
• Study First Submitted QC: 2005-09-01
• Study First Posted: 2005-09-02
• Study Completion: 2007-05
• Status Verified: 2008-12
• Last Update Submitted: 2008-12-31
• Last Update Posted: 2009-01-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 13

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Static physicians global assessment (PGA) and quality of life as measured by DLQI

Trial Locations

Locations (1)

UMDNJ Clinical Research Center; 🇺🇸 New Brunswick, New Jersey, United States